Causes of Hair Loss in Men: Genetics, Hormones, and Beyond

Male hair loss affects an estimated 50 million men in the United States, according to the American Academy of Dermatology (AAD), making it one of the most prevalent dermatological concerns in adult medicine. The causes range from inherited hormonal sensitivity at the follicle level to autoimmune conditions, nutritional deficiencies, and mechanical stress. Understanding the distinct mechanisms behind each cause is essential for matching the right diagnostic framework to the right treatment pathway, a subject explored in depth across the Hair Restoration Authority.

Definition and Scope

Hair loss in men — clinically termed alopecia — encompasses any process that reduces scalp hair density, shaft diameter, or growth cycle duration beyond normal physiological shedding. The AAD identifies normal hair shedding at approximately 50 to 100 strands per day; loss exceeding that threshold consistently signals a pathological process.

The scope of male hair loss spans five primary etiological categories:

  1. Androgenetic alopecia (AGA) — genetically driven, hormone-mediated follicle miniaturization
  2. Alopecia areata — T-cell–mediated autoimmune attack on the hair follicle
  3. Traction and mechanical alopecia — structural damage from chronic tension or trauma
  4. Scarring (cicatricial) alopecia — permanent follicle destruction via fibrosis or inflammation
  5. Telogen effluvium — systemic stressor–induced premature shift of follicles into the resting phase

Classification matters clinically because scarring alopecias permanently destroy follicle architecture, while non-scarring forms typically leave follicles structurally intact and responsive to treatment. The regulatory context for hair restoration governs how diagnostic and treatment claims are made within the US market.

How It Works

Androgenetic Alopecia: The Dominant Mechanism

Androgenetic alopecia accounts for approximately 95% of hair loss in men, per the AAD. The mechanism centers on dihydrotestosterone (DHT), a potent androgen produced when the enzyme 5-alpha reductase converts free testosterone. In genetically susceptible follicles — predominantly those in the frontal scalp and vertex — DHT binds to androgen receptors and progressively shortens the anagen (growth) phase while extending the telogen (resting) phase. Over successive cycles, the follicle miniaturizes: terminal hairs become finer, shorter vellus hairs until growth ceases entirely.

The genetic susceptibility is polygenic, meaning it involves contributions from multiple loci. The androgen receptor gene on the X chromosome (AR gene, chromosome Xq11-12) carries one of the most studied associations, though genome-wide association studies published in journals such as PLOS Genetics have identified more than 287 independent genetic signals contributing to AGA risk.

The Norwood Scale provides the standard clinical classification tool, mapping AGA progression from Stage I (minimal recession) through Stage VII (extensive crown and frontal loss), and directly informs candidacy assessments for surgical intervention.

Autoimmune Mechanism: Alopecia Areata

Alopecia areata results from CD8+ T-lymphocyte infiltration into the follicle bulb. Immune privilege — the normal mechanism by which follicles suppress immune recognition — collapses, triggering follicle damage without permanent structural destruction in most cases. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates alopecia areata affects approximately 2% of the US population at some point in their lifetime. Patchy, well-demarcated loss characterizes the most common presentation, though totalis (complete scalp loss) and universalis (full body loss) variants exist.

Telogen Effluvium

Telogen effluvium follows a systemic insult — major surgery, high fever, severe psychological stress, rapid weight loss, or iron deficiency — that forces a disproportionate share of follicles into the telogen phase simultaneously. The resulting diffuse shedding typically appears 2 to 4 months after the triggering event and resolves without intervention once the stressor is removed, provided no secondary AGA is accelerated.

Scarring Alopecias

Conditions including lichen planopilaris, frontal fibrosing alopecia, and discoid lupus erythematosus destroy follicles through chronic inflammation and fibrotic replacement. The American Hair Loss Association recognizes scarring alopecias as irreversible without treatment of the underlying inflammatory process; hair transplantation into actively inflamed zones carries significant failure risk.

Common Scenarios

Scenario 1 — Early AGA with Active Progression: A male in his mid-20s presents with bitemporal recession and vertex thinning classified at Norwood Stage III. DHT-mediated miniaturization is ongoing. Medical management with FDA-approved agents such as finasteride (1 mg oral, approved 1997) or topical minoxidil (approved 1988) is the first-line consideration before any surgical evaluation. The finasteride for hair loss and minoxidil for hair loss pages detail mechanisms and approval status.

Scenario 2 — Patch Loss with Intact Density Elsewhere: Sharply bordered oval patches without follicle scarring suggest alopecia areata. Dermatoscopy typically reveals exclamation-mark hairs at patch margins. NIAMS notes that spontaneous regrowth occurs in a significant portion of limited-patch cases, particularly when the total affected area is under 50%.

Scenario 3 — Diffuse Shedding 3 Months Post-Illness: Diffuse loss across the entire scalp following a systemic illness is consistent with telogen effluvium. Trichoscopy shows no miniaturization; serum ferritin and thyroid-stimulating hormone (TSH) panels rule out nutritional and endocrine contributors.

Scenario 4 — Recession at Hairline Temples With Inflammatory Plaques: Fibrosis along the frontal hairline margin with perifollicular erythema suggests frontal fibrosing alopecia, a scarring subtype. Biopsy and dermatology referral are required before considering any reconstructive approach.

Decision Boundaries

Not every hair loss presentation is appropriate for surgical restoration. Four decision-relevant distinctions govern evaluation:

  1. Scarring vs. non-scarring: Scarring alopecias require disease quiescence — typically 1 to 2 years of stable, non-progressive inflammation — before follicular unit transplantation can be considered, per guidance from the International Society of Hair Restoration Surgery (ISHRS).
  2. Active progression vs. stabilized loss: Transplanting into a scalp with active AGA progression without concurrent medical therapy risks future native hair loss surrounding grafted zones, creating unnatural appearance over time.
  3. Extent and donor reserve: Norwood Stage VI and VII patients have limited donor hair density relative to recipient demand. Donor reserve assessment is a mandatory pre-procedure step as outlined in FUE candidacy evaluation.
  4. Systemic vs. localized etiology: Telogen effluvium, thyroid dysfunction, and iron-deficiency–related loss require medical correction of the root cause, not surgical intervention; operating during active systemic loss wastes grafts.

The androgenetic alopecia explained page provides a deeper mechanistic breakdown of DHT-follicle interaction, while the alopecia areata page covers autoimmune-specific restoration considerations.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)